Picture this: you started taking Ozempic or Wegovy for type 2 diabetes or weight loss, maybe sometime in 2022 or 2023 when these drugs were everywhere. Then something went wrong. Your stomach stopped working the way it should, leaving you hospitalized with severe nausea and vomiting that doctors eventually diagnosed as gastroparesis. Or you woke up one morning with blurred vision in one eye, and after a terrifying round of tests, learned you’d developed a condition called NAION, a form of optic nerve damage that can cause permanent vision loss. You reported it to your doctor. You maybe even reported it to Novo Nordisk. And then you waited, wondering if anyone else was experiencing this, wondering if you had any recourse at all.

A lot has happened since then. And if that scenario sounds familiar, right now, June 2026, is a moment you genuinely cannot afford to ignore.

The Litigation Just Crossed a Threshold That Changes Everything

ProceedingMDL NumberFocus AreaCourtJudgeStatus as of June 2026
Original MDLMDL No. 3094Gastrointestinal injuries (gastroparesis)Eastern District of Pennsylvania-3,763 pending cases
Vision-Loss MDLMDL No. 3163NAION (optic nerve damage)Eastern District of PennsylvaniaJudge Karen MarstonApproved December 2025; Science Day held June 2, 2026

Here’s where things stand. There are currently two separate federal court proceedings consolidating Ozempic and Wegovy injury claims. The original MDL (that’s multidistrict litigation, essentially a federal system that bundles similar lawsuits together for efficiency), MDL No. 3094, covers gastrointestinal injury claims like gastroparesis. As of June 1, 2026, it holds 3,763 pending cases in the Eastern District of Pennsylvania, up 127 cases from just the month before, according to Drugwatch’s June 2026 litigation update. That growth rate tells you something: attorneys are still actively signing clients, and the case pool is expanding, not contracting.

The second proceeding, MDL No. 3163, is newer and covers vision-loss claims, specifically NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy, a mouthful, but essentially a stroke-like event affecting the optic nerve). The U.S. Judicial Panel on Multidistrict Litigation approved this separate MDL in December 2025, and it’s assigned to Judge Karen Marston in the same Pennsylvania court.

On June 2, 2026, Judge Marston held what’s called a Science Day for the NAION litigation. Both sides got 2.5 hours each to walk the court through the underlying science in a non-adversarial format, not a debate, just an explanation. This is a significant procedural milestone. Judges use Science Days to get up to speed before making critical rulings about what expert testimony will be allowed at trial. It signals that this litigation is moving, not stalled.

Why the Science Is Increasingly on Plaintiffs’ Side

Recommended AMORNING 276-Piece First Aid Kit

Portable first aid kit with 276 pieces covering wounds, sprains, and basic trauma care.

Check Price →

Helpful resource: Pendaflex Portable File Box for Legal Documents is a top-rated option for this. (As an Amazon Associate this site earns from qualifying purchases.)

What most people don’t realize is that the legal question in these cases isn’t just whether you got hurt. It’s whether Novo Nordisk knew, or should have known, about these risks and adequately warned patients and doctors. That’s called a failure-to-warn claim, and the science behind it has gotten significantly stronger in the past year.

In June 2025, the European Medicines Agency concluded that semaglutide, the active ingredient in both Ozempic and Wegovy, doubles a patient’s risk of developing NAION. That finding from a major regulatory body in the European Union carries real weight in American courtrooms. Plaintiffs’ attorneys are leaning on it hard, and understandably so. If regulators across the Atlantic identified a doubled risk, the argument becomes: what did Novo Nordisk know, when did they know it, and why didn’t American patients get a clearer warning?

The gastroparesis cases rest on similar logic. Plaintiffs argue the company knew about the drug’s effects on gastric motility (how fast food moves through your digestive system) and didn’t adequately communicate the severity of those risks to prescribing physicians or patients. I’ve seen cases where the gap between what a company’s internal data shows and what ends up on a warning label is the entire lawsuit. That’s the territory this litigation is in.

What “Bellwether Trials” Mean for You Practically

You’ll see this term a lot if you start researching this litigation: bellwether trials. Here’s what it actually means for real people. In a large MDL, courts don’t try every single case. Instead, both sides pick a small group of representative cases to try first. Those verdicts signal to everyone, plaintiffs, defendants, and their insurers, what a jury thinks about the claims. They’re essentially test cases, and their outcomes almost always drive global settlement discussions.

Bellwether trials in the Ozempic/Wegovy litigation are currently scheduled for late 2026 and into early 2027, according to the Lawsuit Information Center’s May 2026 update. That timeline matters to you for a concrete reason: once those trials start producing verdicts, settlement negotiations typically intensify fast. People who are already in the litigation when that happens are positioned very differently than people who are still thinking about filing.

No global settlement has been reached as of June 2026. But mass tort attorneys tracking this case project individual settlement values ranging from $50,000 to over $700,000, depending heavily on injury severity, the strength of medical documentation, and how clearly your records link your diagnosis to the drug, according to TorHoerman Law’s 2026 settlement projections. Those are projections, not guarantees, and this is exactly the kind of question to ask an attorney who handles mass tort cases specifically.

Who Actually Qualifies and What You Need to Document

I want to be straightforward with you here because I’ve watched people assume they don’t qualify when they might, and I’ve also watched people overestimate their claims. General eligibility for these cases typically requires that you took Ozempic, Wegovy, or another GLP-1 receptor agonist and suffered a documented, diagnosed injury, specifically gastroparesis or NAION. Not general nausea. Not weight fluctuations. A formal diagnosis, documented in your medical records.

The documentation piece is everything. Courts and, eventually, settlement administrators will look at your prescription history (pharmacy records work), your medical records showing diagnosis and treatment, records of hospitalization if applicable, and any record of you or your doctor reporting the adverse event. If you haven’t already, request your complete medical records from every provider who treated your injury. Get your pharmacy records. Hold onto everything.

Statute of limitations is a real deadline, not a soft suggestion. These vary by state, and some run two years from the date you knew or should have known your injury was connected to the drug. If you’ve been sitting on this, talk to an attorney soon. Many mass tort attorneys handle these cases on contingency, meaning no upfront cost to you, they take a percentage if you recover. A consultation costs you nothing and tells you where you stand.

The Window Is Real

The frustrating thing about complex litigation like this is that it moves slowly right up until it moves very fast. Science Day happened June 2. Bellwether trials are on the calendar for later this year. The case count is still growing, which means attorneys are still actively investigating and filing. But that window closes, and the people who acted early when documentation was fresh, memories were clear, and statutes of limitations hadn’t expired are the ones who tend to fare best.

If you or someone you love took semaglutide-based drugs and experienced gastroparesis or vision loss, please don’t wait for a headline to tell you it’s time to act. Talk to a mass tort attorney, ask about your specific timeline, and understand your options. You deserve to make that decision with full information, not find out later that a deadline quietly passed.

Sources

This article is for general informational purposes only and does not constitute legal advice. Laws vary by state. Consult a licensed personal injury attorney in your jurisdiction for advice specific to your situation. Most personal injury attorneys offer free consultations.

Disclosure: As an Amazon Associate, we earn a small commission from qualifying purchases at no extra cost to you. We only recommend products that genuinely support the topics covered in this article.